Kenox Pharmaceuticals, a US-based pharmaceutical company, has added small-scale non-sterile GMP capabilities to support GLP pre-clinical studies as part of its drug development services.
This strategic expansion reinforces the company’s commitment to accelerating the journey from molecule to clinic.
The move aims to equip partners with the necessary tools and expertise to bring life-changing therapies to market more swiftly.
The new capability includes clean room for compounding, fill-finish and release of non-sterile nasal sprays, and dry powders.
This strategic expansion reinforces the company’s commitment to accelerating the journey from molecule to clinic
Kenox is also planning further expansion to facilitate small-scale GMP batch manufacturing for clinical trials (Phase I and II) of both non-sterile and sterile OINDPs.
These new capabilities will help streamline and de-risk the early stages of drug development for its partners and clients, offering a seamless, end-to-end solution from molecule to clinic.
With these new capabilities, Kenox Pharmaceuticals Inc. is well positioned to support a wide range of OINDP dosage forms across various therapeutic areas, including cardiology, psychiatry, antimicrobial and antiviral treatments, pain management, and rare diseases.
Backed by a strong track record and deep expertise in formulation design, pre-clinical and clinical manufacturing, and regulatory support, Kenox provides an end-to-end solution for biopharmaceutical innovators.
These new capabilities will help streamline and de-risk the early stages of drug development for its partners and clients
Its flexibility and scalability enable it to serve both start-ups and large pharmaceutical companies with equal efficiency.
Sitaram Velaga, Founder, President, and CEO at Kenox Pharmaceuticals, said: “I'm so excited about this expansion which was executed in a timely manner. This would not have been possible without our talented and capable team, rockstar QA, support from our partners/clients, various vendors, and the facility management.
“This expansion reflects our dedication to support our partners in their mission to develop cutting edge therapeutics for unmet medical needs with meticulous attention to quality, efficiency, project goals, and timelines.”